Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption

Cholesterol absorption inhibition (CAI) represents an important treatment option for hypercholesterolemia. Herein, we report the design and evaluation of a series of substituted oxazolidinones as ligands for the Niemann Pick C1 Like 1 (NPC1L1) protein, a key mediator of cholesterol transport. Novel analogs were initially evaluated in a brush border membrane NPC1L1 binding assay; subsequently, promising compounds were evaluated in vivo for acute inhibition of cholesterol absorption. These studies identified analogs with low micromolar NPC1L1 binding affinity and acute in vivo efficacy of >50% absorption inhibition at 3 mg/kg.

This manuscript describes the synthesis and evaluation of a series of oxazolidinone-based NPC1L1 ligands for the inhibition of cholesterol absorption.Figure optionsDownload as PowerPoint slide